Non-convulsive Status Epilepticus Clinical Trial
Official title:
Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility
Identify the most effective dose of valproic acid when used in combination with phenytoin for treatment of patients with refractory status epilepticus, which allow a better clinical course and prognosis of the disease.
Phase III Clinical trial, to identify the most effective dose of valproic acid (20mg/kg
bolus, 1mg/kg/h maintenance vs 40mg/kg bolus, 2mg/kg/h maintenance) in combination with
phenytoin, in patients with refractory status epilepticus.
Multicenter clinical trial, single-blind, prospective, randomized 1:1 assignment.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05263674 -
Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)
|
Phase 3 | |
Recruiting |
NCT05418634 -
Point-of-care EEG in the Pediatric Emergency Department
|